| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4028459 | Ophthalmology | 2008 | 7 Pages |
Abstract
These findings confirm the increase in vitreous VEGF and SDF-1α levels in eyes with vascularly active stage 4 ROP. Anti-VEGF treatment may be of benefit in some eyes that develop ROP.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Kenan MD, Kimberly A. MD, PhD, Antonio MD, Michael T. MD,